Abstract

We assessed ceftaroline disk diffusion breakpoints for Staphylococcus aureus when applying revised Clinical and Laboratory Standards Institute (CLSI) ceftaroline MIC breakpoints. Disk-MIC correlation was evaluated by testing a challenge collection (n = 158) of methicillin-resistant S. aureus (MRSA) isolates composed of 106 randomly selected isolates plus 52 isolates with decreased susceptibility to ceftaroline (MIC, 1 to 16 μg/ml). Disk diffusion was performed with 30-μg disks and Mueller-Hinton agar from 2 manufacturers each. Revised CLSI susceptible (S)/susceptible dose-dependent (SDD)/resistant (R) MIC breakpoints of ≤1/2 to 4/≥8 μg/ml were applied. The disk breakpoints that provided the lowest error rates were CLSI S/R breakpoints of ≥25 mm/≤19 mm, with no very major (VM) or major (Ma) errors and with minor (Mi) error rates of 0.0% for ≥2 doubling dilutions above the I or SDD (≥I + 2), 22.1% for I or SDD plus or minus 1 doubling dilution (I ± 1), and 2.3% for ≤2 doubling dilutions below the I or SDD ≤I - 2 (overall Mi error rate, 16.5%). No mutation in the penicillin-binding protein 2a (PBP2a) was observed in 5 of 15 isolates with a ceftaroline MIC of 2 μg/ml; 3 of 11 isolates with a ceftaroline MIC of 1 μg/ml exhibited mutations in the penicillin-binding domain (PBD; 1 isolate) or in the non-PBD (2 isolates). All isolates except 1, with a ceftaroline MIC of ≥4 μg/ml, showed ≥1 mutation in the PBD and/or non-PBD. In summary, results from the disk diffusion method showed a good correlation with those from the reference broth microdilution method. Our results also showed that the ceftaroline MIC distribution of isolates with no mutations in the PBP2a goes up to 4 μg/ml, and reference broth microdilution and disk diffusion methods do not properly separate wild-type from non-wild-type isolates.

Highlights

  • We assessed ceftaroline disk diffusion breakpoints for Staphylococcus aureus when applying revised Clinical and Laboratory Standards Institute (CLSI) ceftaroline MIC breakpoints

  • The organism collection comprised a subset of 106 methicillin-resistant S. aureus (MRSA) isolates that were randomly selected from a collection of 1,596 MRSA clinical isolates recovered from non-U.S countries during the SENTRY program for 2016 and a subset of 52 clinical MRSA isolates with elevated ceftaroline MIC values (1 to 16 ␮g/ml) that were included to provide a better evaluation of the categorical agreement between results from disk diffusion and broth microdilution methods

  • When error rates were analyzed for each disk separately, both disks displayed acceptable error rates, with no major or very major errors, and they had minor error rates of 0.0%, 14.2%, and 4.5% for disks were obtained from Hardy/MAST (disk A) and 0.0%, 29.6%, and 0.0% for disk B at ՆI ϩ 2, I Ϯ 1, and ՅI Ϫ 2, respectively

Read more

Summary

Introduction

We assessed ceftaroline disk diffusion breakpoints for Staphylococcus aureus when applying revised Clinical and Laboratory Standards Institute (CLSI) ceftaroline MIC breakpoints. Disk-MIC correlation was evaluated by testing a challenge collection (n ϭ 158) of methicillin-resistant S. aureus (MRSA) isolates composed of 106 randomly selected isolates plus 52 isolates with decreased susceptibility to ceftaroline (MIC, 1 to 16 ␮g/ml). All isolates except 1, with a ceftaroline MIC of Ն4 ␮g/ ml, showed Ն1 mutation in the PBD and/or non-PBD. Results from the disk diffusion method showed a good correlation with those from the reference broth microdilution method. Our results showed that the ceftaroline MIC distribution of isolates with no mutations in the PBP2a goes up to 4 ␮g/ml, and reference broth microdilution and disk diffusion methods do not properly separate wildtype from non-wild-type isolates

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.